Drug Type Diagnostic radiopharmaceuticals, Radionuclide Drug Conjugates (RDC) |
Synonyms (64)Cu-NOTA-AE105 |
Target |
Action modulators |
Mechanism uPAR modulators(Urokinase plasminogen activator surface receptor modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Glioblastoma | Preclinical | Denmark | 26 May 2023 |





